Company: LENZ
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001193125-25-100630
Chunk: 36

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 36
---
soliciting material” or specifically incorporates it by reference. -21-

EXECUTIVE OFFICERS The following table sets forth certain information about our executive officers as of April 14, 2025.

| Name                  |     | Age |     | Position                                                    |
| Evert Schimmelpennink |     |  53 |     | Chief Executive Officer, President, Secretary, and Director |
| Shawn Olsson          |     |  42 |     | Chief Commercial Officer                                    |
| Marc Odrich           |     |  66 |     | Chief Medical Officer                                       |
| Daniel Chevallard     |     |  45 |     | Chief Financial Officer                                     |

For the biography of Mr. Schimmelpennink, please see “ Board of Directors and Corporate Governance – Continuing Directors.” Shawn Olssonhas served as our Chief Commercial Officer since March 2024. Mr. Olsson served as LENZ OpCo’s Chief Commercial Officer from April 2021 through the closing of the Merger. Previously, from March 2018 to April 2021, Mr. Olsson served as Vice President of North American Marketing and Global Portfolio and Vice President of North American Marketing at Xellia Pharmaceuticals, a pharmaceuticals and life sciences company. From September 2015 to March 2018, Mr. Olsson served as Director, Global Sterile Injectables on Market Strategy Lead and Commercial Lead, Opioids and Syringe Technology Portfolio at Pfizer (NYSE: PFE), a multinational pharmaceutical and biotechnology company. Mr. Olsson holds a B.S. in Mechanical Engineering from Purdue University, a M.S. in Mechanical Engineering from University of Michigan and an M.B.A. in Strategic Management and Finance from University of Chicago. Marc Odrich, M.D.has served as our Chief Medical Officer since March 2024. Dr. Odrich served as LENZ OpCo’s Chief Medical Officer from July 2021 through the closing of the Merger and provided consulting services to LENZ OpCo from March 2018 to July 2021. Since June 2017, Dr. Odrich has served as an Associate Professor of Ophthalmology at the University of Virginia, where he specializes in Refractive Surgery and Ocular Surface Disease. Since March 2016, Dr. Odrich has served as a consultant to TearSolutions, Inc., an early stage clinical ophthalmology company specializing in Ocular Surface Disease. Dr. Odrich is a